Ovarian Cancer – Unmet Need – Unmet Need – Recurrent Platinum-Resistant Ovarian Cancer (US EU)

The treatment landscape for advanced platinumresistant ovarian cancer remains highly challenging, as conventional singleagent chemotherapies provide limited and shortlived benefit. Unlike the progress seen in platinumsensitive disease, effective and durable options for platinumresistant patients are scarce. A key recent advance has been the introduction of mirvetuximab soravtansine for FRαhigh tumors, marking the first meaningful targeted therapy in this setting and highlighting the potential for biomarkerdriven approaches. However, for the broader population without high FRα expression, therapeutic choices remain few, and response rates remain low, reinforcing the substantial unmet need that continues to define platinumresistant ovarian cancer.

QUESTIONS ANSWERED

• Which attributes most influence physicians’ prescribing decisions in the treatment of platinum-resistant ovarian cancer?
• How do medical oncologists rate the performance of therapies, such as mirvetuximab soravtansine, on key treatment drivers and goals for this patient population?
• What are the prevailing areas of unmet need in the treatment of platinum-resistant ovarian cancer?
• What trade-offs across different clinical attributes and prices are acceptable to surveyed medical oncologists for a hypothetical treatment of platinum-resistant ovarian cancer?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in March 2026

Key drugs: Mirvetuximab soravtansine

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.

KEY FEATURE

Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.